Reports Q1 revenue $695,000, consensus $1.12M. “In the first quarter of 2025, we presented data from our Phase 2 studies in chronic spontaneous and chronic inducible urticaria that demonstrated that barzolvolimab greatly improved quality of life for patients,” said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex (CLDX) Therapeutics. “Barzolvolimab has consistently demonstrated best-in-class efficacy in chronic urticaria, with very high rates of complete response, and it’s especially meaningful to see these results translate into improved quality of life for patients living with a severe disease that impacts nearly every aspect of their daily lives.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Optimistic Buy Rating for Celldex Driven by Promising Barzolvolimab Developments and Strong Financial Position
- Promising Phase 2 Results for Celldex’s Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating
- Celldex presents histology data from barzolvolimab study
- Hasbro, Rithm, Boeing, Valero, Celldex: Trending by Analysts
- Celldex Therapeutics (CLDX) Q1 Earnings Cheat Sheet
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue